Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call on February 24, 2022, at 8:30 a.m. ET to discuss its financial results for the year ending December 31, 2021. Interested participants can join by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international) with conference ID 1792414. A live audio webcast will also be available on the company’s website. A replay will be accessible for seven days post-call at designated numbers. Amicus focuses on developing high-quality medicines for rare metabolic diseases.

Positive

• Scheduled conference call to discuss full-year financial results.
• Focus on advancing a robust pipeline of medicines for rare metabolic diseases.

Negative

• None.

PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2021.

Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 1792414. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

A replay of the call will be available for seven days beginning at 11:30 a.m. ET. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 1792414.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

When is the Amicus Therapeutics conference call?

The conference call is scheduled for February 24, 2022, at 8:30 a.m. ET.

How can I access the Amicus Therapeutics conference call?

Participants can call 877-303-5859 (U.S./Canada) or 678-224-7784 (international) using conference ID 1792414.

What will be discussed in the Amicus Therapeutics conference call?

The call will cover the financial results for the full year ended December 31, 2021.

Will there be a replay of the Amicus Therapeutics conference call?

Yes, a replay will be available for seven days after the call at specific access numbers.

What is the focus of Amicus Therapeutics?

Amicus Therapeutics is dedicated to developing novel medicines for people with rare metabolic diseases.